Levobetaxolol Hydrochloride Eye Drops for Treatment of Primary Open-angle Glaucoma or Ocular Hypertension

To evaluate the safety and efficacy of Levobetaxolol in Chinese patients with primary open-angle glaucoma or ocular hypertension.

Inclusion criteria

• Agreed to participate in this clinical trial and informed consent;
• Aged 18 to 70 years of age, male or female;
• In line with primary open-angle glaucoma diagnostic criteria, IOP ≥18mmHg;
• or in compliance with ocular hypertension diagnostic criteria, intraocular pressure> 21mmHg

Exclusion criteria

• Known or suspected to be allergic to investigational drugs and materials
• has been diagnosed with angle-closure glaucoma, absolute glaucoma, glaucoma ciliary body syndrome, secondary glaucoma.
• merge various retinal lesions, such as retinal detachment, retinal vein occlusion, retinitis pigmentosa.
• merge associated with eye infections or cornea, iris, lens obvious lesions, or one-eyed patients.
• During the trial who must wear contact lenses, or nearly three months experts any eye surgery or laser treatment.
• Need systemic β-blocker therapy during the study.
• with severe kidney disease, or abnormal liver function tests (ALT, AST≥ 1.5 times the upper limit of normal, SCr> upper limit of normal).
• merge sinus bradycardia, over Ⅰ degree atrioventricular block, cardiogenic shock, heart failure, symptomatic hypotension or other serious heart, lung diseases (such as bronchial asthma or a history of bronchial asthma, chronic obstructive lung disease, bronchospasm, respiratory failure, etc.).
• merge hyperthyroidism, myasthenia gravis, diabetes, advanced cancer, blood and hematopoietic system diseases, or other serious or progressive disease systems.
• associated with neurological and psychiatric disorders
• suspect or indeed alcohol, drug abuse history.
• pregnancy, lactation or recent fertility planner.
• The researchers believe other circumstances were not involved in this trial.
• participate in other clinical trials within three months.